Use of chlorhexidine dihydrochloride in the preparation of antitumor drugs

Chlorhexidine dihydrochloride blocks the interaction between MYCN protein and PARP1 by binding to a specific site, thereby degrading MYCN protein. This solves the problem of treating high-risk neuroblastoma, significantly inhibits tumor growth and metastasis, and has good prospects for clinical application.

CN122398769APending Publication Date: 2026-07-17XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Filing Date
2026-05-13
Publication Date
2026-07-17

Smart Images

  • Figure CN122398769A_ABST
    Figure CN122398769A_ABST
Patent Text Reader

Abstract

本发明涉及氯己定二盐酸盐在制备抗肿瘤药物中的应用，本发明发现氯己定二盐酸盐（简称CHD）作为MYCN‑PARP1相互作用抑制剂，能够通过直接结合PARP1蛋白第770位天冬氨酸位点，阻断PARP1与MYCN的蛋白互作，进而解除PARP1对MYCN蛋白稳定性的保护作用，最终促进MYCN经由泛素‑蛋白酶体途径降解，抑制MYCN扩增型神经母细胞瘤的增殖、侵袭和转移。本发明为干预MYCN蛋白稳定性来治疗神经母细胞瘤提供了新的药理策略，尤其发现了CHD可通过阻断MYCN‑PARP1互作来促进MYCN降解，进而拓展了CHD在肿瘤治疗领域中的新用途。
Need to check novelty before this filing date? Find Prior Art